Inhibition of renal fibrosis with a human CXCL9‐derived glycosaminoglycan‐binding peptide
暂无分享,去创建一个
G. Opdenakker | P. Proost | M. Albersen | J. Van Damme | B. Sprangers | S. Struyf | Helena Crijns | Fariba Poosti | Vincent Vanheule | M. Metzemaekers | N. Berghmans | A. De Zutter | M. Soebadi | Mieke Metzemaekers | Alexandra De Zutter
[1] V. Tesar,et al. Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal , 2019, Kidney and Blood Pressure Research.
[2] F. Tacke,et al. Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications. , 2019, Molecular aspects of medicine.
[3] G. Opdenakker,et al. Anti‐inflammatory effects of the GAG‐binding CXCL9(74‐103) peptide in dinitrofluorobenzene‐induced contact hypersensitivity in mice , 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[4] P. Proost,et al. The chemokine fragment CXCL9(74–103) diminishes neutrophil recruitment and joint inflammation in antigen‐induced arthritis , 2018, Journal of leukocyte biology.
[5] Yau-Huei Wei,et al. Essential role of connective tissue growth factor (CTGF) in transforming growth factor-β1 (TGF-β1)-induced myofibroblast transdifferentiation from Graves’ orbital fibroblasts , 2018, Scientific Reports.
[6] N. Vaziri,et al. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[7] P. Proost,et al. Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands , 2018, Front. Immunol..
[8] M. Mack. Inflammation and fibrosis. , 2017, Matrix biology : journal of the International Society for Matrix Biology.
[9] P. Boor,et al. PDGF in organ fibrosis. , 2017, Molecular aspects of medicine.
[10] P. Ryan,et al. CXCL9-11 polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross-sectional study , 2017, Clinical and Translational Medicine.
[11] P. Proost,et al. Glycosaminoglycans Regulate CXCR3 Ligands at Distinct Levels: Protection against Processing by Dipeptidyl Peptidase IV/CD26 and Interference with Receptor Signaling , 2017, International journal of molecular sciences.
[12] Paul Martin,et al. Inflammation and metabolism in tissue repair and regeneration , 2017, Science.
[13] Weiping Zou,et al. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy , 2017, Nature Reviews Immunology.
[14] P. Kubes,et al. CXCL9-Derived Peptides Differentially Inhibit Neutrophil Migration In Vivo through Interference with Glycosaminoglycan Interactions , 2017, Front. Immunol..
[15] S. Samsonov,et al. Sulfated Hyaluronan Derivatives Modulate TGF-β1:Receptor Complex Formation: Possible Consequences for TGF-β1 Signaling , 2017, Scientific Reports.
[16] C. Chung,et al. Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis , 2016, International journal of nanomedicine.
[17] P. Proost,et al. Basic chemokine-derived glycosaminoglycan binding peptides exert antiviral properties against dengue virus serotype 2, herpes simplex virus-1 and respiratory syncytial virus. , 2016, Biochemical pharmacology.
[18] A. Fabre,et al. CXCL9 Regulates TGF-β1–Induced Epithelial to Mesenchymal Transition in Human Alveolar Epithelial Cells , 2015, The Journal of Immunology.
[19] P. Proost,et al. The Positively Charged COOH-terminal Glycosaminoglycan-binding CXCL9(74–103) Peptide Inhibits CXCL8-induced Neutrophil Extravasation and Monosodium Urate Crystal-induced Gout in Mice* , 2015, The Journal of Biological Chemistry.
[20] P. E. Van den Steen,et al. CXCR3 ligands in disease and therapy. , 2015, Cytokine & growth factor reviews.
[21] A. Kungl,et al. A Combinatorial Approach to Biophysically Characterise Chemokine-Glycan Binding Affinities for Drug Development , 2014, Molecules.
[22] E. Tredget,et al. The Role of Chemokines in Fibrotic Wound Healing. , 2014, Advances in wound care.
[23] Douglas B. Evans,et al. Chemokines and chemokine receptors: update on utility and challenges for the clinician. , 2014, Surgery.
[24] S. Rennard,et al. Matrix metalloproteinase-9 activates TGF-β and stimulates fibroblast contraction of collagen gels. , 2014, American journal of physiology. Lung cellular and molecular physiology.
[25] W. Teughels,et al. Citrullination and Proteolytic Processing of Chemokines by Porphyromonas gingivalis , 2014, Infection and Immunity.
[26] J. Van Damme,et al. CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase , 2014, Angiogenesis.
[27] A. Mantovani,et al. International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors , 2014, Pharmacological Reviews.
[28] H. Wasmuth,et al. Chemokines in tissue fibrosis. , 2013, Biochimica et biophysica acta.
[29] S. Alexander,et al. Matrix metalloproteinase-9 of tubular and macrophage origin contributes to the pathogenesis of renal fibrosis via macrophage recruitment through osteopontin cleavage , 2013, Laboratory Investigation.
[30] S. Friedman,et al. Therapy for Fibrotic Diseases: Nearing the Starting Line , 2013, Science Translational Medicine.
[31] M. Trinker,et al. Targeting chemokine-glycan interactions: the CellJammer(®) technology platform. , 2012, Drug discovery today. Technologies.
[32] Youliang Wang,et al. Renal tubular epithelial cell injury, apoptosis and inflammation are involved in melamine-related kidney stone formation , 2012, Urological Research.
[33] P. Proost,et al. Overview of the mechanisms regulating chemokine activity and availability. , 2012, Immunology letters.
[34] B. Thornhill,et al. Fight-or-flight: murine unilateral ureteral obstruction causes extensive proximal tubular degeneration, collecting duct dilatation, and minimal fibrosis. , 2012, American journal of physiology. Renal physiology.
[35] Fabian Kiessling,et al. Chemokine Cxcl9 attenuates liver fibrosis‐associated angiogenesis in mice , 2012, Hepatology.
[36] R. Kalluri,et al. Mechanistic connection between inflammation and fibrosis. , 2010, Kidney international. Supplement.
[37] R. Homer,et al. Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. , 2010, The Journal of clinical investigation.
[38] M. T. Grande,et al. Role of inflammation in túbulo-interstitial damage associated to obstructive nephropathy , 2010, Journal of Inflammation.
[39] F. Tacke,et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. , 2009, Gastroenterology.
[40] A. Rek,et al. Therapeutically targeting protein–glycan interactions , 2009, British journal of pharmacology.
[41] L. Liaw,et al. Osteopontin: A Multifunctional Molecule Regulating Chronic Inflammation and Vascular Disease , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[42] Youhua Liu,et al. Renal fibrosis: new insights into the pathogenesis and therapeutics. , 2006, Kidney international.
[43] T. Handel,et al. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. , 2005, Cytokine & growth factor reviews.
[44] T. Handel,et al. Regulation of protein function by glycosaminoglycans--as exemplified by chemokines. , 2005, Annual review of biochemistry.
[45] A. Imberty,et al. Heparan Sulfate/Heparin Oligosaccharides Protect Stromal Cell-derived Factor-1 (SDF-1)/CXCL12 against Proteolysis Induced by CD26/Dipeptidyl Peptidase IV* , 2004, Journal of Biological Chemistry.
[46] R. Homer,et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. , 2004, The Journal of clinical investigation.
[47] U. V. von Andrian,et al. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. , 2004, Annual review of immunology.
[48] B. Hinz,et al. Myofibroblasts and mechano-regulation of connective tissue remodelling , 2002, Nature Reviews Molecular Cell Biology.
[49] G. Jayson,et al. Heparan sulfate proteoglycans and cancer , 2001, British Journal of Cancer.
[50] A. Zlotnik,et al. Chemokines: a new classification system and their role in immunity. , 2000, Immunity.
[51] I. Stamenkovic,et al. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.
[52] M. Lyon,et al. The Interaction of the Transforming Growth Factor-βs with Heparin/Heparan Sulfate Is Isoform-specific* , 1997, The Journal of Biological Chemistry.
[53] J. Farber. HuMig: a new human member of the chemokine family of cytokines. , 1993, Biochemical and biophysical research communications.
[54] A. Billiau,et al. Human Fibroblast Interferon for Clinical Trials: Production, Partial Purification, and Characterization , 1979, Antimicrobial Agents and Chemotherapy.
[55] P. Proost,et al. Chapter 1. Isolation, identification, and production of posttranslationally modified chemokines. , 2009, Methods in enzymology.
[56] Youhua Liu. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. , 2004, Journal of the American Society of Nephrology : JASN.
[57] A. Zlotnik,et al. The biology of chemokines and their receptors. , 2000, Annual review of immunology.